Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - dorzolamidum, timololum - acu pilieni, šķīdums - 20 mg/5 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - kandesartāna cileksetils - tablete - 16 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - perindoprila tosilāts - apvalkotās tabletes - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - quinaprilum, hydrochlorothiazidum - apvalkotās tabletes - 10 mg/12,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - klaritromicīns - ilgstošās darbības tabletes - 500 mg

Latvija - latviešu - Zāļu valsts aģentūra

teva pharma b.v., netherlands - perindoprila tosilāts - apvalkotās tabletes - 5 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetāts - diagnostikas metodes, endokrīnās - macimorelīns - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

recordati ireland ltd - silodosin - prostatas hiperplāzija - urologicals, alfa-adrenoreceptor antagonistiem - Ārstēšanu, simptomi un pazīmes, labdabīgas prostatas hiperplāzijas (bph) pieauguši vīrieši.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

ražots Ķīnā pēc vp laboratory ltd. the south quay building 189 marsh wall, london, e14 9sh, uk pasūtījuma - kapsula